CPR introduces retail price report
MARIETTA, Ga. — A provider of competitive market intelligence and insights has introduced a report that is designed to provide manufacturers and retailers instant access to U.S. retail prices of more than 12,000 SKUs in the health, beauty and wellness industry.
Competitive Promotion Report said its retail price report, is designed to provide accurate, everyday retail prices without the expense and hassle of having field staff conduct surveys and compile the data. The files, which are updated monthly, offer retail prices across four channels, including mass, grocery, drug and independents, and also provides a range of retail prices within each of these channels (low, average and high), CPR said.
For more information, contact [email protected] or call 877-491-4949.
FDA approves drug for severe epilepsy
SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating a severe form of epilepsy, the agency said Monday.
The FDA announced the approval of Onfi (clobazam) tablets, made by Catalent Pharma Solutions and Lundbeck, as an add-on treatment for seizures associated with Lennox-Gastaut syndrome in patients ages 2 years and older. The agency gave the drug orphan drug designation because the disease affects fewer than 200,000 people in the United States.
"This is a difficult condition to treat, and it will be helpful to have an additional treatment option," FDA Division of Neurology Products director Russell Katz said.
Investigational Sanofi drug shows improvements in MS patients
CAMBRIDGE, Mass. — More than three-quarters of patients with multiple sclerosis using a drug made by Sanofi subsidiary Genzyme did not experience disease relapse for two years, according to results of a late-stage clinical trial revealed over the weekend.
The drug maker announced Saturday results of the "CARE-MS I" trial, the first of two phase-3 clinical trials comparing the investigational drug Lemtrada (alemtuzumab) with Pfizer’s and EMD Serono’s Rebif (interferon beta-1a) in patients with relapsing-remitting MS.
Data from the trial showed that after two years, 78% of patients taking Lemtrada remained relapse-free, compared with 59% of those taking Rebif.